Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin

ClinicalTrials.gov ID: NCT00242372

Public ClinicalTrials.gov record NCT00242372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral antidiabetic agents in addition to diet and lifestyle advice). The study comprises a 3-week enrollment period and a 24-week randomized, double blind, multi-center, placebo-controlled treatment period and a 3-week follow-up. Patients must receive at least 30 units of insulin per day and will continue their current oral antidiabetic treatment regimen throughout the study.

Study identification

NCT ID
NCT00242372
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
370 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2004
Primary completion
Not listed
Completion
Feb 28, 2006
Last update posted
Apr 21, 2009

2004 – 2006

United States locations

U.S. sites
71
U.S. states
31
U.S. cities
71
Facility City State ZIP Site status
Research Site Birmingham Alabama
Research Site Phoenix Arizona
Research Site Tuscson Arizona
Research Site Fresno California
Research Site Greenbrae California
Research Site La Jolla California
Research Site Northridge California
Research Site Riverside California
Research Site San Diego California
Research Site Santa Monica California
Research Site Spring Valley California
Research Site Walnut Creek California
Research Site West Hills California
Research Site Waterbury Connecticut
Research Site Washington D.C. District of Columbia
Research Site Gainesville Florida
Research Site Hollywood Florida
Research Site Jacksonville Florida
Research Site Miami Florida
Research Site Orlando Florida
Research Site Palm Harbor Florida
Research Site West Palm Beach Florida
Research Site Augusta Georgia
Research Site Dunwoody Georgia
Research Site Boise Idaho
Research Site Chicago Illinois
Research Site Chicago Heights Illinois
Research Site Gurnee Illinois
Research Site Maywood Illinois
Research Site Springfield Illinois
Research Site Indianapolis Indiana
Research Site Wichita Kansas
Research Site New Orleans Louisiana
Research Site Baltimore Maryland
Research Site Bethesda Maryland
Research Site Cadillac Michigan
Research Site Richmond Heights Missouri
Research Site St Louis Missouri
Research Site Omaha Nebraska
Research Site North Las Vegas Nevada
Research Site Pahrump Nevada
Research Site Dover New Hampshire
Research Site Roseland New Jersey
Research Site Albuquerque New Mexico
Research Site Brooklyn New York
Research Site New Hyde Park New York
Research Site Charlotte North Carolina
Research Site Wilmington North Carolina
Research Site Cincinnati Ohio
Research Site Kettering Ohio
Research Site Toledo Ohio
Research Site Oklahoma City Oklahoma
Research Site Medford Oregon
Research Site Portland Oregon
Research Site Altoona Pennsylvania
Research Site Cheswick Pennsylvania
Research Site Erie Pennsylvania
Research Site Philadelphia Pennsylvania
Research Site Columbia South Carolina
Research Site Greer South Carolina
Research Site Corpus Christie Texas
Research Site Dallas Texas
Research Site Fort Worth Texas
Research Site Houston Texas
Research Site San Antonio Texas
Research Site Richmond Virginia
Research Site Bellevue Washington
Research Site Renton Washington
Research Site Spokane Washington
Research Site Tacoma Washington
Research Site Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00242372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2009 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00242372 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →